journal article·2015-04Open access

Investigation into the safety of perineural application of 1,4‐butanediol diglycidyl ether‐crosslinked hyaluronan in a rat model

Sheng‐Min Lan, I‐Ming Jou, Po‐Ting Wu, Cheng‐Yi Wu, Sung‐Ching Chen

Abstract

Abstract Hyaluronan (HA) is well known for its biocompatibility and has widespread clinical use. To change its mechanical and physiologic properties to adapt to specific clinical scenarios, HA is crosslinked with chemically reactive linker molecules, most of which are toxic chemical reagents. Adverse events related to clinical use of crosslinked HA have been documented. Although approved by the FDA as dermal filler, the safety of perineural application of 1,4‐butanediol diglycidyl ether (BDDE)‐crosslinked HA has not been assessed critically. Concern exists owing to the vulnerability of neural tissues, because of their elongated morphology, high ratio of membrane surface area to cell volume, and complicated electrophysiologic properties. In this study, we systematically investigated the toxicity profile of BDDE‐crosslinked HA, usingin vitroandin vivoexperiments in a rat model. Thein vivoexperiments included the evaluation of aspects of histopathology, electrophysiology, and neurobehavior. There were no significant changes in the treatment group compared with the control group in all aspects of the experiments, except for the increased epineurial vascular formation in the 0.5% crosslinked HA‐treated group during 2 weeks of observation. Further studies involving perineural application of BDDE‐crosslinked HA can be done based on our findings, which ruled out the safety concern of cytotoxicity and adverse changes in electrophysiology and neurobehavior. © 2014 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 103B: 718–726, 2015.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Connective tissue disorders research · Proteoglycans and glycosaminoglycans research · Corneal Surgery and Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Institute of Clinical Medicine National Cheng Kung University No.1, University Road, Tainan 70101 Taiwan

Department of Orthopaedics College of Medicine, National Cheng‐Kung University Tainan 70428 Taiwan

Department of Orthopaedics Chia Yi Christian Hospital Chia Yi Taiwan

R&D Division Direction Maxigen Biotech Inc., Wugu District New Taipei City 248 Taiwan

References (37)

Show source-provided references
1. 10.1016/j.jviscsurg.2011.11.00610.1016/j.jviscsurg.2011.11.006 ↗
2. 10.1097/00006254-200405000-0002410.1097/00006254-200405000-00024 ↗
3. 10.1055/s-0031-127247510.1055/s-0031-1272475 ↗
4. 10.1055/s-0031-129878510.1055/s-0031-1298785 ↗
5. 10.1111/j.1473-2165.2009.00464.x10.1111/j.1473-2165.2009.00464.x ↗
6. 10.1016/j.cps.2012.07.00710.1016/j.cps.2012.07.007 ↗
7. 10.1111/j.1524-475X.2012.00777.x10.1111/j.1524-475X.2012.00777.x ↗
8. 10.1002/art.2310310.1002/art.23103 ↗
9. 10.1001/jama.290.23.311510.1001/jama.290.23.3115 ↗
10. 10.1088/1748-6041/7/2/02410110.1088/1748-6041/7/2/024101 ↗
11. 10.2174/13892011280062442710.2174/138920112800624427 ↗
12. 10.1615/CritRevTherDrugCarrierSyst.v15.i5.3010.1615/CritRevTherDrugCarrierSyst.v15.i5.30 ↗
13. 10.1016/j.carres.2007.08.02110.1016/j.carres.2007.08.021 ↗
14. Matereial safety data sheet of 1 4‐butanediol diglycidyl ether. Sigma‐Aldrich; 2013. Accessed on April 17 2014. Available at:http://www.sigmaaldrich.com/MSDS/MSDS/DisplayMSDSPage.do?country=TW&language=en&productNumber=220892&brand=ALDRICH&PageToGoToURL=http%3A%2F%2Fwww.sigmaaldrich.com%2Fcatalog%2Fproduct%2Faldrich%2F220892%3Flang%3Den.
15. 10.1016/j.biomaterials.2003.12.01210.1016/j.biomaterials.2003.12.012 ↗
16. 10.1097/SAP.0b013e31824f21da10.1097/SAP.0b013e31824f21da ↗
17. 10.1186/1423-0127-17-810.1186/1423-0127-17-8 ↗
18. 10.1007/s10557-012-6402-410.1007/s10557-012-6402-4 ↗
19. 10.1097/01.BRS.0000107228.17075.B910.1097/01.BRS.0000107228.17075.B9 ↗
20. 10.1097/BRS.0b013e3181453fa510.1097/BRS.0b013e3181453fa5 ↗
21. 10.1002/(SICI)1098-2752(1998)18:2<119::AID-MICR10>3.0.CO;2-010.1002/(SICI)1098-2752(1998)18:2<119::AID-MICR10>3.0.CO;2-0 ↗
22. 10.1177/175319341039076010.1177/1753193410390760 ↗
23. 10.17221/1930-VETMED10.17221/1930-VETMED ↗
24. 10.1002/(SICI)1097-4636(199711)37:2<243::AID-JBM14>3.0.CO;2-F10.1002/(SICI)1097-4636(199711)37:2<243::AID-JBM14>3.0.CO;2-F ↗
25. 10.1002/jbm.b.3010610.1002/jbm.b.30106 ↗
26. 10.1002/art.2302610.1002/art.23026 ↗
27. 10.1097/00001665-200303000-0001110.1097/00001665-200303000-00011 ↗
28. 10.1016/j.joca.2012.03.02010.1016/j.joca.2012.03.020 ↗
29. 10.1080/0192623039020436010.1080/01926230390204360 ↗
30. 10.1097/01.blo.0000152443.04202.4310.1097/01.blo.0000152443.04202.43 ↗
31. 10.2106/00004623-200209000-0001510.2106/00004623-200209000-00015 ↗
32. DeLisaJA GansBM WalshNE.Physical Medicine and Rehabilitation: Principles and Practice: Lippincott Williams & Wilkins;Philadelphia PA 2004.
33. Rheological blends for drug delivery. II. Prolongation of nerve blockade, biocompatibility, and in vitro‐in vivo correlations10.1002/jbm.a.32420 ↗
34. 10.1016/j.biomaterials.2011.12.03110.1016/j.biomaterials.2011.12.031 ↗
35. Nerve regeneration following spinal cord injury using matrix metalloproteinase‐sensitive, hyaluronic acid‐based biomimetic hydrogel scaffold containing brain‐derived neurotrophic factor10.1002/jbm.a.32519 ↗
36. Angiogenesis in a delayed revascularization model is accelerated by angiogenic oligosaccharides of hyaluronan
37. 10.1126/science.240834010.1126/science.2408340 ↗